{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tamoxifen&page=6",
    "query": {
      "condition": "Tamoxifen",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 148,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tamoxifen&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tamoxifen&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:13:05.175Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06184750",
      "title": "Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Atypical Ductal Hyperplasia",
        "Breast Atypical Lobular Hyperplasia",
        "Breast Carcinoma",
        "Breast Ductal Carcinoma In Situ",
        "Breast Lobular Carcinoma In Situ",
        "Estrogen Receptor-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2024-09-27",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06184750"
    },
    {
      "nct_id": "NCT00026585",
      "title": "Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2001-11-09",
      "completion_date": "2007-11-02",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026585"
    },
    {
      "nct_id": "NCT02197897",
      "title": "Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-04-01",
      "completion_date": "2019-06-28",
      "has_results": true,
      "last_update_posted_date": "2021-01-13",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197897"
    },
    {
      "nct_id": "NCT02278120",
      "title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 59 Years · Female only"
      },
      "enrollment_count": 672,
      "start_date": "2014-11-20",
      "completion_date": "2023-04-20",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 35,
      "location_summary": "Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278120"
    },
    {
      "nct_id": "NCT00293540",
      "title": "Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "International Breast Cancer Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 249,
      "start_date": "2006-02",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00293540"
    },
    {
      "nct_id": "NCT06195306",
      "title": "Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Atypical Hyperplasia",
        "Breast Carcinoma",
        "Breast Ductal Carcinoma In Situ",
        "Breast Lobular Carcinoma In Situ"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Omega-3-Acid Ethyl Esters",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Random Periareolar Fine-Needle Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "74 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 74 Years · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2025-07-28",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06195306"
    },
    {
      "nct_id": "NCT04190056",
      "title": "Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-03-11",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2023-08-31",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04190056"
    },
    {
      "nct_id": "NCT00749138",
      "title": "Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bader, Ted, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2010-03-09",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749138"
    },
    {
      "nct_id": "NCT00952731",
      "title": "4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ductal Breast Carcinoma in Situ",
        "Estrogen Receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "oral placebo",
          "type": "DRUG"
        },
        {
          "name": "afimoxifene",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2009-12",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-07-21",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00952731"
    },
    {
      "nct_id": "NCT00349011",
      "title": "Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menopause"
      ],
      "interventions": [
        {
          "name": "Personalized risk assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "genetic counseling intervention",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2002-08",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-11-15T12:13:05.175Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349011"
    }
  ]
}